


Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



RESECTABLE

EA2197/OPT-IN

Gemcitabine + Cisplatin: Neo
+ Adjuvant or Adjuvant only

Coord: N. Ferrand
Accrual: 0/10

FIRST LINE

UCI 22-212 (includes Ampullary)

Durvalumab + any
gemcitabine-based regimen

Coord: N. Ferrand
Accrual: 1/8

UCI 22-211 MED1572 (IgG1 mAb) or AZD2936 (TIGIT) ± gemcitabine and cisplatin

Coord: C. Kang
Accrual: 1/8

SECOND LINE+

ETCTN-10276 M3814 ± Avelumab + Hypofraction Radiation

Coord: N. Ferrand
Accrual: 1/5

SECOND LINE+ (INTRAHEPATIC)

UCI 23-24 HAI SD-101 + Pembro or Nivo

IRB, budget, and contract
pending + amendment

PERIOPERATIVE

A021806
Neo/adjuvant vs adjuvant
mFOLFIRINOX

Coord: N. Ferrand
 Accrual: 0/15

UCI 22-75
ELI-002 7P (oncolytic virus)
(KRAS Local testing)
 Within 6 months of resection

Coord: M. Duron
 Accrual: 0/7

BORDERLINE/LOCALLY ADVANCED

ETCTN-10366
 M3814 (Peposertib) +
 radiation therapy

Coord: H. Nguyen
 Accrual: 4/8

ETCTN-10464
Olaparib with Durvalumab +
radiation therapy

Coord: H. Nguyen
 Accrual: 0/5

RECURRENT METASTATIC

ETCTN 10522
CA4948 + gemcitabine + nab-
paclitaxel

Coord: H. Nguyen
 Accrual: 3/4

MUTATION BASED

UCI 22-171
EGFR TriNKET +/- Nivolumab
(Central testing)

Coord: M. Nguyen
 Accrual: 3/15

UCI 22-51
 ASP2138 (CLDN18.2)

IRB, budget, CTA pending

S2001
Olaparib +/- Pembrolizumab
(BRCA 1/2)

Coord: J. Balague
 Accrual: 2/4


ADJUVANT


S2104

Capecitabine + Temozolomide
vs observation

Pancreatic NET

Coord: J. Balangue
Accrual: 0/2





PROGRESSED, ALL THERAPIES EXHAUSTED, OR NOT AMENABLE TO TREATMENT

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: N. Ferrand
Accrual: 6/12

UCI 23-07

P-MUC1C-ALLO1 (CAR-T Cell)

IRB, budget, contract
pending

UCI 22-37

TACH101 (KDM4C inhibitor)

Phase 1: all solid tumors

Coord: A. Luna
Accrual: 3/10

SYSTEMIC AND/OR IO NAIVE

UCI 23-91

INCB099280 (Oral CPI) + Ipilimumab

Phase 1: HCC, ccRCC, Melanoma, MSI-H/dMMR Colorectal

Expansion: HCC, ccRCC, systemic and immunotherapy naive

IRB, budget, contract pending

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: J. Balague
Accrual: 10/15

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Pending IRB

UCI 20-101

(Biospecimen Collection for
patients planned to start IO
treatment)

Coord: J. Koff
Accrual: 53/80

SUPPORTIVE

UCI 22-109

Palonosetron IV vs. Buccal film
anti-emetic

Coord: P. Yang
Accrual: 1/30